We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biovail Corporation and Athpharma Limited announced the amicable termination of their joint development agreement related to four development-stage cardiovascular products.
The law firm of Brower Piven, a professional association, announced that a securities class action was commenced on behalf of shareholders who purchased, converted, exchanged or otherwise acquired the common stock of Par Pharmaceutical Companies, Inc. between April 29, 2004 and July 5, 2006, inclusive (the "Class Period").
Genentech, Inc. and Inotek Pharmaceuticals Corporation announced that they have entered into an exclusive global collaboration to discover, develop, manufacture and commercialize inhibitors of poly (ADP-ribose) polymerase (PARP) for the potential treatment of cancer.
Gov. Arnold Schwarzenegger proposed a prescription drug plan that would penalize pharmaceutical companies that fail to provide big discounts to low-income Californians within five years by limiting their access to the state's huge Medi-Cal market.
The FDA has given fast-track status to a post-surgical drug being developed by Wyeth Pharmaceuticals and Progenics Pharmaceuticals, the companies said July 17.
The FDA is attempting to place itself in the growing debate over the independence of its advisory committee members and head off potential legislative changes with its announcement of a slate of new guidances.
Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc., has announced the commercial availability of Opana ER and Opana tablets.